secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0000950170-24-073609
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health: 26% monthly volume growth, expanded Anthem & Medicaid, lower 2024 cash burn
--------------------------------------------------------------------------------

- OvaSuite product volume grew >26% in May 2024 vs January 2024; OvaWatch volume YTD up >88% vs 2023.
- Anthem contracts expanded to CT, NH, ME, adding 2M lives; total 9M Anthem lives, expects 16M more.
- Maryland and Kentucky added OvaWatch to Medicaid fee schedule at $897/test; nine states now cover OvaSuite.
- Philippines OvaWatch commercial launch on track for Q3 2024; fee-per-test model expected to yield higher margins.
- Company expects to lower 2024 cash used in operations guidance on Q2 2024 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000095017024073609/0000950170-24-073609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000095017024073609/awh-20240613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer